MRI

Gadoteridol (Gd-HP-DO3A) is a gadolinium-based MRI contrast agent that can be used for central nervous system imaging.

Gadobutrol is a nonionic, paramagnetic contrast agent developed for tissue contrast enhancement in magnetic resonance imaging (MRI)

(Rac)-Zevaquenabant ((Rac)-MRI-1867, compound 6b) is a potent and selective antagonist of cannabinoid receptor type 1 (CB1R) and inducible nitric oxide synthase (iNOS), with a binding affinity (Ki) of 5.7 nM for CB1R. It holds promise as an investigative tool in liver fibrosis research due to these characteristics.

Zevaquenabant ((S)-MRI-1867), a dual cannabinoid CB1 receptor and inducible NOS (iNOS) antagonist, is orally bioavailable and peripherally restricted. It effectively mitigates obesity-induced chronic kidney disease (CKD).

Monlunabant is a selective CB1 antagonist that blocks CB1 receptor signaling to reduce appetite and fat accumulation, making it suitable for research on obesity and metabolic syndrome. Monlunabant binds to hCB1 and hCB2 with Ki values of 0.3 nM and 613 nM, respectively.

(R)-Monlunabant ((R)-MRI-1891) is a CB1 receptor antagonist used in obesity and metabolic disease research [1].

(R)-Zevaquenabant ((R)-MRI-1867) is the enantiomer of Zevaquenabant. Zevaquenabant ((S)-MRI-1867) is a peripherally restricted, orally bioavailable dual antagonist of the cannabinoid CB1 receptor and inducible nitric oxide synthase (iNOS). It is beneficial in improving chronic kidney disease (CKD) caused by obesity.

AMRI-59 is a potent inhibitor of [PrxI] possessing anti-tumor activity.

Amrinone (Inocor) is a positive inotropic cardiotonic (cardiotonic agent) with vasodilator properties, phosphodiesterase 3 inhibitory activity.

MMRi6 is an inhibitor of the Mdm2-MdmX RING domain, capable of disrupting Mdm2-MdmX RING-RING interactions in vitro. It inhibits MdmX-stimulated Mdm2 autoubiquitination and Mdm2-MdmX-mediated polyubiquitination of p53 without affecting NEDD4-1 autoubiquitination. In wt-p53 Emu-myc lymphoma cells, MMRi6 induces p53 stabilization and accumulation, as well as PARP cleavage. It inhibits the growth of wt-p53 and p53-null Emu-myc lymphoma cells, with IC50 values of approximately 0.5 μM and 3 μM, respectively. MMRi6 is applicable in leukemia/lymphoma research.

MMRi64 is a specific inhibitor of Mdm2-MdmX E3 ligase activity.MMRi64 potently induces p53 accumulation and apoptosis in the p53 pathway in leukemia/lymphoma cells, disrupts Mdm2-MdmX interactions, and downregulates Mdm2 and MdmX in leukemia cells.MMRi64 MMRi64 can be used in cancer research.

MRIA9, an ATP-competitive inhibitor targeting pan Salt-Inducible Kinases (SIK) and PAK2/3, demonstrates IC50 values of 516 nM, 180 nM, and 127 nM for SIK1, SIK2, and SIK3, respectively [1].

MMRi62 (7-[(2,3-dichlorophenyl)-(pyridin-2-ylamino)methyl]quinolin-8-ol), a ferroptosis inducer targeting MDM2-MDM4 (negative regulators of tumor suppressor p53). MMRi62 shows a P53-independent pro-apoptotic activity against pancreatic ductal adenocarcinoma (PDAC) cells and induce autophagy. MMRi62 inducesferroptosis, resulting in a increase of reactive oxygen and lysosomal degradation of ferritin heavy chain (FTH1). MMRi62 also leads to proteasomal degradation of mutant p53, also inhibits orthotopic xenograft PDAC mouse model in vivo with high frequency mutation characteristics of KRAS and TP53.12.

Emricasan (IDN-6556) is a pan-caspase inhibitor with irreversible properties. Emricasan has anti-inflammatory and anti-apoptotic activity and can be used in the treatment of infections and liver failure, etc. Emricasan also inhibits Zika virus infections.

Inamrinone lactate is a positive inotropic cardiotonic with vasodilator properties, phosphodiesterase inhibitory activity, and the ability to stimulate calcium ion influx into the cardiac cell.

Tamrintamab (SC-003 mAb) is an antibody targeting dipeptidase 3 (DPEP3), a potential cytotoxic agent for ovarian cancer research.

α-Conotoxin MrIC is a biased agonist selective for the α7 nicotinic acetylcholine receptor (nAChR), with activation contingent upon the presence of type II positive allosteric modulators, such as PNU120596. It is utilized to investigate neurological disorders and delineate the pharmacological characteristics of the α7nAChR [1].

Simlukafusp alfa (Simridarlimab) is a humanized immunoglobulin antibody that targets the CD274/PD-L1 and CD47 pathways.[1]

(2R,3S)-Emricasan ((2R,3S)-PF 03491390) is an isomer of Emricasan. This compound acts as an orally effective irreversible pan-caspase inhibitor. (2R,3S)-Emricasan inhibits the increase in caspase-3 activity induced by Zika virus (ZIKV) and protects human cortical neural progenitor cells.

Zamristobart is a humanized IgG4κ antibody that targets LILRB1 (leukocyte immunoglobulin-like receptor B1) and exhibits both immune-stimulating and antitumor properties. The suggested isotype control is HumanIgG4(S228P) kappa, Isotype Control.

Oxytetracycline (Terramycin) is a TETRACYCLINE analog isolated from the actinomycete STREPTOMYCES rimosus and used in a wide variety of clinical conditions.

Oxytetracycline Hydrochloride (Dalimycin) is a tetracycline derivative produced by Streptomyces rimosus with antimicrobial activity. It interferes with the binding of aminoacyl-tRNA to the mRNA-ribosome complex, resulting in preventing peptide elongation and inhibiting protein synthesis.

Oxytetracycline Dihydrate (Terramycin Dihydrate) is a prescription antibiotic, interfering with the ability of bacteria to produce essential proteins.

Sabcomeline, a potent and functionally selective partial agonist at muscarinic M1 receptors, enhances cognition and is utilized in Alzheimer's disease research [1] [2].